Diethyl({6-[({[4-(hydroxycarbamoyl)phenyl]carbamoyl}oxy)methyl]naphthalen-2-YL}methyl)azanium hydrate chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Diethyl({6-[({[4-(hydroxycarbamoyl)phenyl]carbamoyl}oxy)methyl]naphthalen-2-YL}methyl)azanium hydrate chloride
• 英文别名: diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride;hydrate
• 化学式: C24H30ClN3O5
• 分子量: 476.0
• InChiKey: FKGKZBBDJSKCIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.15
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  91.9
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• Method for treating Philadelphia-negative myeloproliferative syndromes
  申请人：Mascagni Paolo

  公开号：US20110237663A1

  公开（公告）日：2011-09-29

  A method for treating Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea to a patient in need of such a treatment, is described. The diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride in combination with N-hydroxyurea induces positive therapeutic responses in patients refractory to the N-hydroxyurea monotherapy and/or whose therapeutic response to monotherapy with the same dose of N-hydroxyurea is unsatisfactory.
• US8217079B2
  申请人：——

  公开号：US8217079B2

  公开（公告）日：2012-07-10